Fundz

Oligomerix reported raising in an initial SEC Form D filing, from an offering of $650,000

PRIVATEDec 06, 2024$0 of $650K raised

Round Type

Series B

White PlainsHealthcare

Who else raised in Healthcare around the same time

Companies in the same sectors as Oligomerix that raised within 45 days of this round, from Fundz verified event records.

  • Imagen Dental Partners raised $516K on January 9, 2025.
  • Geneoscopy raised $105M (Series C) on January 8, 2025.
  • iotaMotion raised $6.4M on January 8, 2025.
  • Fruit Street Health raised $100K on January 8, 2025.
  • Microbot Medical raised $7M on January 7, 2025.
  • NewcelX raised $500K (Seed) on January 7, 2025.

Who to call at Oligomerix, and when

A new round usually means Oligomerix is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Oligomerix raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Oligomerix, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Oligomerix. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Oligomerix

Location

2 WESTCHESTER PARK DRIVE

White Plains, New York, United States

About

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Oligomerix raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJack P., DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Oligomerix's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Oligomerix raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.